The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).
 
Jaclyn P. Lyman
No Relationships to Disclose
 
Christopher R Cabanski
No Relationships to Disclose
 
Stephen Maddock
No Relationships to Disclose
 
Robert A. Wolff
Honoraria - Conveners; Emirates Oncology Society; Modern Medicine
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Arcus Biosciences; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; QED Therapeutics; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Andrew H. Ko
Honoraria - BioAscent; Clinical Care Options; Gerson Lehrman Group; Medscape; MJH Life Sciences; Research to Practice
Consulting or Advisory Role - ERYTECH Pharma; Five Prime Therapeutics; Imugene; Ipsen; Roche/Genentech; Signatera; SynCoreBio; Syros Pharmaceuticals; Turning Point Therapeutics; Tyme
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CrystalGenomics (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst)
 
Osama E. Rahma
Employment - AstraZeneca/MedImmune; Outcomes4me
Leadership - AstraZeneca/MedImmune; Outcomes4me
Stock and Other Ownership Interests - AstraZeneca/MedImmune; Outcomes4Me
Honoraria - Alaunus Global; Clinical Care Options; Leerink; Merck; MI Bioresearch; PRMA Consulting
Consulting or Advisory Role - Alcimed; Bayer; Celgene; Defined Health; Five Prime Therapeutics; Genentech; Gfk; GlaxoSmithKline; Imvax; Leerink; Leerink; Maverick Therapeutics; Merck; PureTech; Putnam Associates; Sobi
Research Funding - Amgen (Inst); Merck
Patents, Royalties, Other Intellectual Property - PD-1/PD-L1 (Inst); Pending patent (DFCI 2386.010) (Inst)
Travel, Accommodations, Expenses - Clinical Care Options; Genentech; Merck; PRMA Consulting; PureTech
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Honoraria - echina health
Consulting or Advisory Role - Genentech/Roche; Ipsen; Merck; Taiho Pharmaceutical
Research Funding - Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
Other Relationship - AstraZeneca; CytomX Therapeutics; Hutchison MediPharma; Silenseed; Taiho Pharmaceutical; Terumo Clinical Supply
 
Peter Edward Gabriel
Travel, Accommodations, Expenses - Varian Medical Systems; Varian Medical Systems
 
Abigail Doucette
No Relationships to Disclose
 
Binbin Zheng-Lin
No Relationships to Disclose
 
Molly A. Maloy
No Relationships to Disclose
 
Ute Dugan
No Relationships to Disclose
 
Justin P. Fairchild
Employment - Portage Biotech
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Marko Spasic
Employment - IDEAYA Biosciences
Consulting or Advisory Role - Natera
 
Jill O'Donnell-Tormey
Leadership - Coherus Biosciences
Stock and Other Ownership Interests - Coherus Biosciences
Travel, Accommodations, Expenses - Coherus Biosciences
 
Robert H. Vonderheide
Patents, Royalties, Other Intellectual Property - Inventor on a licensed patient regarding cancer vaccine antigens; Receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody
 
Mark H. O'Hara
Consulting or Advisory Role - Geneos; Natera; PsiOxus Therapeutics
Research Funding - Arcus Biosciences; Bristol-Myers Squibb; Celldex; Geneos; Lilly; Natera; Parker Institute for Cancer Immunotherapy; PsiOxus Therapeutics
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca; Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen; Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma